Amrita Blickstead'un ücretlendirmesi SomnoMed'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$624k	AU$167k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$11m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$91k	n/a	-AU$8m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	AU$91k	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$5m
Dec 31 2021	n/a	n/a	-AU$5m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	AU$32k	n/a	-AU$1m

Tazminat ve Piyasa: Amrita 'nin toplam tazminatı ($USD 390.47K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 291.28K ).

Tazminat ve Kazançlar: Amrita şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Amrita Blickstead

4.3yrs

Görev süresi

AU$624,323

Tazminat

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Amrita Blickstead	Co-CEO & Executive Director	no data	AU$624.32k	0.49% A$ 453.6k
Karen Borg	Co-CEO & Executive Director	no data	AU$693.50k	0.24% A$ 218.5k
Mark Harding	Vice President of Global Marketing	5.4yrs	AU$483.37k	0.067% A$ 61.5k
Matthew Conlon	Executive VP of Sales & Marketing - North America	5.2yrs	AU$427.31k	Veri yok
Marco Van Kleef	Vice President of Marketing & Sales - Europe	no data	AU$589.17k	Veri yok
Ye-Fei Guo	Chief Financial Officer	less than a year	Veri yok	Veri yok
Terence Flitcroft	Company Secretary	29.9yrs	AU$10.56k	Veri yok
Christopher Bedford	Vice President of Global Production and Product Development	no data	AU$128.07k	Veri yok

5.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: SOM 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Amrita Blickstead	Co-CEO & Executive Director	4.3yrs	AU$624.32k	0.49% A$ 453.6k
Karen Borg	Co-CEO & Executive Director	4.1yrs	AU$693.50k	0.24% A$ 218.5k
Michael Gordon	Non-Executive Director	4.3yrs	AU$92.38k	0.10% A$ 95.6k
Iven Klineberg	Member of the Medical Advisory Board	no data	Veri yok	Veri yok
J. Gerschman	Member of the Medical Advisory Board	no data	Veri yok	Veri yok
Peter Cistulli	Chairman of the Medical Advisory Board	no data	Veri yok	Veri yok
Gaetano Russo	Chairman of the Board	4.3yrs	AU$160.96k	0.95% A$ 873.5k
Benjamin Gisz	Non-Executive Director	less than a year	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SOM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 01:02
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

SomnoMed Limited 3 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Russell Wright	APP Securities Pty Ltd.
Peter Meichelboeck	Select Equities Pty Ltd
Dr Storey	Wilsons Advisory and Stockbroking Ltd.

SomnoMed Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chairman of the Board recently bought AU$295k worth of stock

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited Announces Board Changes

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

Recent updates

Chairman of the Board recently bought AU$295k worth of stock

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

New major risk - Share price stability

SomnoMed Limited Revises Earnings Guidance for Fiscal Year 2025

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited Announces Board Changes

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

SomnoMed Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45